Currently, Halozyme Therapeutics Inc [HALO] is trading at $46.84, down -3.62%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HALO shares have lost -1.16% over the last week, with a monthly amount glided 10.03%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Halozyme Therapeutics Inc [NASDAQ: HALO] stock has seen the most recent analyst activity on October 07, 2024, when Wells Fargo downgraded its rating to a Equal Weight and also boosted its price target to $62 from $58. Previously, JP Morgan downgraded its rating to Neutral on September 19, 2024, and elevated its price target to $57. On June 07, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $51 on the stock. TD Cowen started tracking the stock assigning a Outperform rating and suggested a price target of $54 on February 29, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $61 as its price target on July 24, 2023. Goldman downgraded its rating to Neutral for this stock on July 24, 2023, and upped its price target to $45. In a note dated May 10, 2023, Piper Sandler upgraded an Overweight rating on this stock but restated the target price of $46.
This stock has fluctuated between a low of $33.15 and a high of $65.53 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $46.84 at the most recent close of the market. An investor can expect a potential return of 11.02% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Trailing Twelve Months sales for Halozyme Therapeutics Inc [NASDAQ:HALO] were 947.36M which represents 34.28% growth. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.5%, Pretax Profit Margin comes in at 0.51%, and Net Profit Margin reading is 0.41%. To continue investigating profitability, this company’s Return on Assets is posted at 0.19, Equity is 1.56 and Total Capital is 0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.66 points at the first support level, and at 44.48 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.81, and for the 2nd resistance point, it is at 50.78.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Halozyme Therapeutics Inc [NASDAQ:HALO] is 10.36. Further, the Quick Ratio stands at 9.15, while the Cash Ratio is 1.42. Considering the valuation of this stock, the price to sales ratio is 6.29, the price to book ratio is 13.16 and price to earnings (TTM) ratio is 15.50.
Transactions by insiders
Recent insider trading involved LaBarre Michael J., SVP, CHIEF TECHNICAL OFFICER, that happened on Oct 15 ’24 when 10000.0 shares were sold. SVP, CHIEF TECHNICAL OFFICER, LaBarre Michael J. completed a deal on Oct 16 ’24 to sell 10000.0 shares. Meanwhile, Officer MICHAEL LABARRE bought 10000.0 shares on Oct 16 ’24.
